Angiopoietin-like Protein 7/ANGPTL7 Antibody (538401) [Alexa Fluor® 405]

• Applications: WB, IHC
• Clone: 538401
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 405

Angiopoietin-like Protein 7/ANGPTL7 Antibody (538401) [Alexa Fluor® 405] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant mouse Angiopoietin-like Protein 7/ANGPTL7
  Gln22-Pro337 (predicted)
  Accession # Q8R1Q3
• Specificity: Detects mouse Angiopoietin-like Protein 7/ANGPTL7 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) Angiopoietin-like 1, 5, 7, recombinant mouse (rm) Angiopoietin-like 2, 3, 4, 6, rhAngiopoietin-1, rhA
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Angiopoietin-like Protein 7 (ANGPTL7), also known as Corneal-Derived Transcript 6 (CDT6), is a secreted, 45‑50 kDa glycoprotein member of the angiopoietin‑like family of molecules. Members of this protein family contain an N-terminal coiled coil domain and a C-terminal fibrinogen-like domain (1‑3). Mature mouse ANGPTL7 is 316 amino acids (aa) in length. It shares 88% and 98% aa sequence identity with human and rat ANGPTL7, respectively. The ANGPTL7 monomer forms homotetramers via its coiled coil domain (4, 5). ANGPTL7 is expressed in the corneal stroma, trabecular meshwork, and sclera (3, 5). Its production is up‑regulated in trabecular meshwork cells by glucocorticoids and TGF-beta and in cartilage by TNF-alpha (5-7). ANGPTL7 expression is up‑regulated under conditions of increased ocular pressure (IOP). Since IOP is a risk factor for glaucoma, ANGPTL7 may represent a defense mechanism to reduce pressure on the retina. It appears that IOP is a consequence of increased ECM deposition, a major component of which is fibronectin. In this regard, ANGPTL7 is reported to both decrease fibronectin expression and promote MMP1 expression, actions that would tend to reduce organized ECM deposition (8). When overexpressed in tumor cells, it promotes collagen and proteoglycan deposition but inhibits tumor xenograft progression and tumor angiogenesis (4). ANGPTL7, when used in combination with SCF, Thrombopoietin, IGF-II, and FGF acidic, enhances the expansion and engraftment of human and mouse hematopoietic stem cells (9).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.